ABL1 and acute lymphoblastic leukemia: In a study by Clarke et al, a total daily dose of 600 mg imatinib was administered in combination with vincristine and prednisolone to a male T-ALL patient with the NUP214-ABL1 fusion gene who relapsed three months after a sibling allograft (35).